Recently, d’Amore et al. showed that, inside the nodal PTCL, the ALK-negative ALCL subgroup benefits greatly from ASCT, with a 5-year OS of 70% versus 47% and 52% for PTCL-NOS and AITL, respectively [29]. This evidence concerns the gene ALK and angioimmunoblastic T-cell lymphoma.